DB06305InvestigationalProtein Based Therapies
A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P... S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Code names
- LT-1009
Resolves to
Compound
What you can answer from here — as of June 12, 2020
Which companies are running trials of Sonepcizumab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account